32例紫杉醇治疗耐药性乳腺癌  

Paclitaxol for 32 cases with drug resistant mammary carcinoma

作　　者：宋谦[1] 盛信秀[1] 谢剑明[1] 李金瀚[1] 

机构地区：[1]第一军医大学南方医院肿瘤科,广东广州510515

出　　处：《中国癌症杂志》2000年第2期153-154,共2页China Oncology

摘　　要：目的　研究紫杉醇治疗对阿霉素、氟尿嘧啶在内的多种抗癌药耐药患者的临床疗效。　方法　 32例病理证实的乳腺癌患者从前均接受过阿霉素、氟尿嘧啶治疗但无效 ,再给予紫杉醇治疗观察临床疗效。　结果　32例中 ,完全缓解 2例 ,占 6 3 % ,平均缓解期为 6个月。部分缓解 10例 ,占 31 3 % ,平均缓解期 4个月。有效率为37 5 %。　结论　紫杉醇对耐药乳腺癌的疗效较好 ,对于难治性晚期乳腺癌 。Purpose:To investigate the clinical therapeutic effect of paclitaxol on drug resistant mammary carcinoma.Methods:32 cases of mammary carcinoma treated with adriamycin and fluorouracil with no effectiveness were given paclitaxol to observe its effect.Results:Complete response was seen in 2 with a response rate of 6.3% and partial response in 10 with a response rate of 31.3%.The average length of remission was 6 months in complete response and 4 months in partial response.The rate of effectiveness was 37.5%.Conclusions:Paclitaxol is effective in drug resistant mammary carcinoma. It is the first choice in the treatment of refractory advanced mammary carcinoma.

关 键 词：紫杉醇 耐药性 乳腺癌 药物疗法 

分 类 号：R737.905[医药卫生—肿瘤] R730.53[医药卫生—临床医学]